

## Distribution of *Escherichia coli* strains harbouring Shiga toxin-producing *E. coli* (STEC)-associated virulence factors (*stx1*, *stx2*, *eae*, *ehxA*) from very young calves in the North Island of New Zealand

H. IRSHAD<sup>1</sup>\*, A. L. COOKSON<sup>2</sup>, D. J. PRATTLE<sup>1</sup>, M. DUFOUR<sup>3</sup>  
AND N. P. FRENCH<sup>1</sup>

<sup>1</sup>mEpiLab, Hopkirk Research Institute, Massey University, Palmerston North, New Zealand

<sup>2</sup>AgResearch Ltd, Grasslands Research Centre, Palmerston North, New Zealand

<sup>3</sup>Enteric Reference Laboratory, ESR-NCBID, New Zealand

Received 30 May 2013; Final revision 30 September 2013; Accepted 7 January 2014;  
first published online 6 February 2014

### SUMMARY

The objective of this study was to determine the distribution of Shiga toxin-producing *Escherichia coli* (STEC) virulence markers (*stx1*, *stx2*, *eae*, *ehxA*) in *E. coli* strains isolated from young calves aged fewer than 7 days (bobby calves). In total, 299 recto-anal mucosal swabs were collected from animals at two slaughter plants and inoculated onto tryptone bile X-glucuronide and sorbitol MacConkey agar supplemented with cefixime and potassium tellurite. Isolates were analysed using multiplex polymerase chain reaction to detect *stx1*, *stx2*, *eae* and *ehxA* genes. The most common combination of virulence markers were *eae*, *ehxA* ( $n=35$ ) followed by *eae* ( $n=9$ ). In total, STEC and atypical enteropathogenic *E. coli* (aEPEC) were isolated from 8/299 (2.6%) and 37/299 (12.3%) calves, respectively. All the isolates could be assigned to 15 genotype clusters with >70% similarity cut-off using *Xba*I pulsed-field gel electrophoresis. It may be concluded that healthy calves from the dairy industry are asymptomatic carriers of a diverse population of STEC and aEPEC in New Zealand.

**Key words:** Public health, Shiga toxin-producing *E. coli*.

### INTRODUCTION

Shiga toxin-producing *Escherichia coli* (STEC) are considered to be important foodborne pathogens causing outbreaks and sporadic cases of diarrhoea, haemorrhagic colitis (HC) and haemolytic uraemic syndrome (HUS) in humans worldwide [1]. Cattle and sheep are well established reservoirs of STEC where direct contact with infected animals and consumption of contaminated food and water are important pathways for transmission of STEC to humans

[1, 2]. Internationally the majority of human cases are associated with O157 STEC [3] but non-O157 STEC have also been associated with human disease with six non-O157 serogroups, known as the ‘Super Six’ (O26, O45, O103, O111, O121, O145), responsible for 70% of non-O157 human cases in the USA [4]. As a consequence of the threat to human health through the contamination of the environment or food products, the Food Safety and Inspection Service (FSIS) of the USA recently extended the list of meat adulterants by including the Super Six STEC [5].

STEC elaborate a variety of virulence factors including Shiga toxin (*stx*) which inhibits protein synthesis, especially in renal endothelial cells [6], *E. coli* attaching and effacing (*eae*) and enterohaemolysin

\* Author for correspondence: Dr H. Irshad, mEpiLab, Hopkirk Research Institute, Massey University, Palmerston North, New Zealand.  
(Email: h.irshad@massey.ac.nz)

(*ehxA*) genes [7, 8]. The *eae* gene encodes the outer membrane protein intimin [9] which mediates the attachment of *E. coli* to the epithelial lining of intestine and effacement of microvilli [10]. The plasmid-encoded STEC enterohaemolysin, encoded by *ehxA*, is an important virulence marker which can cause haemolysis of washed sheep erythrocytes [11]. The exact role of STEC enterohaemolysin in the mechanism of disease is not clearly understood. However, *in-vitro* studies have shown increased levels of pro-inflammatory cytokine interleukin-1 $\beta$  from human monocytes in response to enterohaemolysin from STEC O128:H12 [12].

In addition to STEC, cattle and sheep are also reservoirs of enteropathogenic *E. coli* (EPEC) [13]. EPEC possess the *eae* gene and hence form attaching and effacing (AE) lesions on cultured epithelial cells *in vitro* but lack *stx* [14]. The formation of micro-colonies on cultured epithelial cells by many typical EPEC (tEPEC) isolated from human diarrhoeal cases is mediated by the bundle-forming pili (*bfpA*). However, atypical EPEC (aEPEC) which lack *bfpA* are commonly recovered from ruminants and may also be associated with human diarrhoeal disease [15].

After the first recorded isolation of STEC in New Zealand in 1980 [16] the rate of infection in New Zealand increased to 1.3 cases/100 000 population in 1998 and 3.5 cases/100 000 population in 2011 [17]. In New Zealand the rate of STEC cases in rural areas is three times higher than the rate in urban areas; however, no large outbreaks have been reported to date with most cases being sporadic [18]. Shiga toxin bacteriophage insertion typing studies in New Zealand have provided further evidence to support the view that environmental and direct contact pathways are likely to be more important in the transmission of STEC to humans than food pathways [19]; in line with the strong association observed between cattle density and the incidence of human STEC cases [18].

The dairy and meat industries make a significant contribution to the New Zealand economy [20] and processing methods, especially in the meat industry, are influenced by meat exportation guidelines imposed by some countries such as the USA, which has a zero tolerance policy for STEC O157 and some non-O157 STEC (The Super Six STEC) in meat [5]. Relatively few data are available to assist in the epidemiological analysis of STEC and EPEC in New Zealand cattle. Therefore, this snapshot study was conducted with the aim of isolating *E. coli* from bobby calves using

recto-anal mucosal swabs (RAMS) to determine the distribution of STEC virulence factors (*stx1*, *stx2*, *eae*, *ehxA*) in randomly chosen isolates. This will also assist in determining whether very young calves may represent a source of STEC or EPEC infection for humans in New Zealand.

## MATERIALS AND METHODS

Two abattoirs (A and B) were selected in the North Island of New Zealand and were each visited six times between July and October 2008 [21]. RAMS (Copan, Italy) were collected systematically from every tenth calf on the chain immediately after slaughter. Twenty-five calves were sampled on each visit and in total 299 calves were sampled.

RAMS were then placed in the transport media provided by the manufacturer and transported to the laboratory on ice where they were enriched in buffered peptone water (BPW) for 24 h at 37 °C. Each enrichment broth was serially diluted 10 000 times ( $10^{-4}$ ) and inoculated onto tryptone bile X-glucuronide (TBX; Fort Richard, New Zealand) and sorbitol MacConkey agar, supplemented with 50  $\mu$ g/ml cefixime and 2.5 mg/ml potassium tellurite (CT-SMAC) to ensure that single, well-spaced colonies could be subcultured for further analysis. Each plate was then incubated at 37 °C for 18–24 h. One blue colony indicative of  $\beta$ -glucuronidase-positive activity and one white colony indicative of  $\beta$ -glucuronidase-negative activity were selected at random from the TBX plates. Similarly, one pink colony indicative of sorbitol-fermenting activity and one grey or colourless colony indicative of sorbitol-non-fermenting activity were selected at random from the CT-SMAC plates. Isolates were subcultured onto the same culture media (CT-SMAC and TBX) to ensure purity, and a single colony was stored at –80 °C in nutrient broth containing 15% (v/v) glycerol.

Isolates were analysed using multiplex polymerase chain reaction (PCR) to detect *stx1*, *stx2*, *eae* and *ehxA* genes. Isolates were re-grown on TBX or CT-SMAC at 37 °C for 18–24 h. A single colony was suspended in 500  $\mu$ l of 2% chelex (Bio-Rad, New Zealand) solution and heated at 95 °C for 10 min for isolation of DNA. The lysed bacterial cell suspension was then cooled in the refrigerator for 2 min and re-centrifuged at 12 000 *g* for 2 min. The supernatant containing the DNA was transferred to another tube. Each PCR reaction contained 1 $\times$  reaction buffer (Invitrogen, New Zealand), 0.2  $\mu$ M of

each primer [22], 0.1 mM of each dNTP (Fermentas, New Zealand), 0.15 mM MgCl<sub>2</sub> (Invitrogen), 1 U *Taq* DNA polymerase (Invitrogen), 2 µl DNA, and made to a final volume of 25 µl with sterile water. The amplification was carried out in a Gene Amp PCR system 9700 (Applied Biosystems, Australia). The cycling conditions for multiplex PCR were: an initial denaturation step for 5 min at 96 °C followed by 40 cycles of 30 s at 96 °C, 30 s at 60 °C, 30 s at 72 °C, with a final extension of 5 min at 72 °C, after which the PCR products were electrophoresed through an agarose (2% w/v) gel (Invitrogen) and visualized using ethidium bromide under ultraviolet illumination.

Isolates positive for the targeted virulence genes were confirmed as being *E. coli* by PCR targeting the alanine racemase gene [23]. Briefly, each PCR reaction contained 1x reaction buffer (Invitrogen), 0.2 µM of each primer (forward: 5'-CTGGAAG-AGGCTAGCCTGGACGAG-3'; reverse: 5'-AAAA-TCGGCACCGGTGGAGCGATC-3'), 0.1 mM of each dNTP (Fermentas), 0.15 mM MgCl<sub>2</sub> (Invitrogen), 1 U *Taq* DNA polymerase (Invitrogen), 2 µl of DNA, and made to a final volume of 20 µl with sterile water. The amplification was carried out in a Rotor Gene 6000 series thermal cycler. It was programmed for an initial denaturation step of 2 min at 94 °C, 25 cycles of 20 s at 94 °C, 20 s at 62 °C, and 20 s at 72 °C and a final extension at 72 °C for 90 s. The PCR products were electrophoresed through an agarose gel (1% w/v) and visualized by staining the gel with ethidium bromide under ultraviolet illumination.

A PCR for the detection of *bfpA* encoding the EPEC major bundle-forming pilus subunit was performed on all *eae*-positive, *stx*-negative isolates. PCR primers *bfpF* (5'-GAAGTAATGAGCGCA-ACGTCTGC-3') and *bfpR* (5'-GGTAAGYGTCAG-ATAGTAACC-3') were designed using the *bfpA* sequence from EPEC strain O127:H6 E2348/69 (Genbank accession no. Z68186) to amplify a 213 bp DNA product. A degenerate base Y was included in the reverse oligonucleotide primer to account for a single nucleotide polymorphism observed at that position in other *bfpA* sequences during primer specificity analysis. Each PCR reaction contained 0.1 µM of each primer, 17.5 µl PCR Platinum Supermix (Invitrogen) and 1.5 µl template DNA. EPEC strain O127:H6 E2348/69 was used as the positive control strain. The amplification was carried out in a Master Cycler proS (Eppendorf AG, Germany) thermal cycler with an initial denaturation step of 2 min at 96 °C, followed by

30 cycles of 96 °C for 30 s, 53 °C for 30 s, and 72 °C for 60 s and a final extension of 72 °C for 10 min. PCR products were viewed as described previously.

Isolates positive for any of the targeted virulence factors were analysed by real-time PCR (qPCR) to amplify genes that are diagnostic for *E. coli* serogroups O26 [24], O103 [25], O111 [24], O145 [26] and O157 [24]. STEC isolates negative for *E. coli* O26, O103, O111, O145 and O157 by qPCR were serotyped by the Enteric Reference Laboratory, ESR, New Zealand using O and H antigens (Statens Serum Institute, Denmark). Sixty isolates containing the targeted virulence genes were genotyped using pulsed-field gel electrophoresis (PFGE) to determine the genetic relatedness of isolates. PFGE was performed following the PulseNet USA protocol [27]. The gel was stained in ethidium bromide (0.5 µg/ml) for 20 min and visualized using short wavelength ultraviolet transillumination. Digital images of the gel were captured using a Gel Doc imaging system (Bio-Rad, Italy) and saved as TIFF files. The digital images were analysed using Bionumeric v. 6.6 (www.applied-maths.com). The unweighted pair-group method with arithmetic mean (UPGMA), Dice coefficient with >70% similarity cut-off, 0.5% optimization and band-matching tolerance were used to construct the clusters of *E. coli* isolates with one or more targeted virulence genes.

The distribution of farms from which the calves that were sampled originated from ( $n=193$ ) were mapped using R package *maptools* (R Development Core Team, R Foundation for Statistical Computing, Austria). The coordinates (latitude and longitude) of the farms ( $n=180$ ) were obtained using *Agribase* data [28] and *Google earth* (www.google.com/earth). The latitude and longitude of each farm was then converted to x,y coordinates. The coordinates of 13 farms were missing. The sampled farms were aggregated to 5 × 5 km grid squares to maintain the anonymity of the farms. The prevalence of calves positive for *E. coli* isolates with one or more targeted virulence genes in three regions (Manawatu, Taranaki, Waikato) of the North Island of New Zealand was estimated and adjusted for the lack of independence of calves within farms using R package 'survey' and function 'svydesign'.

## RESULTS

In total 299 RAMS were collected from bobby calves originating from 193 farms in the North Island of

Table 1. Distribution of the targeted virulence genes (*stx1*, *stx2*, *eae*, *ehxA*) in *E. coli* isolates obtained from recto-anal mucosal swabs ( $n=299$ ) of bobby calves on sorbitol MacConkey agar (CT-SMAC) and tryptone bile X-glucuronide (TBX) plates. Sorbitol-fermenting (SF) and non-sorbitol-fermenting (NSF) colonies were obtained on CT-SMAC plates while  $\beta$ -glucuronidase-positive ( $\beta$ GP) and  $\beta$ -glucuronidase-negative ( $\beta$ GN) colonies were obtained on TBX

Virulence genes	CT-SMAC		TBX		Total
	SF	NSF	$\beta$ GP	$\beta$ GN	
<i>eae</i> , <i>ehxA</i>	27	2	6	0	35
<i>eae</i>	5	0	1	3	9
<i>ehxA</i>	7	0	1	0	8
<i>stx1</i> , <i>eae</i> , <i>ehxA</i>	3	0	0	0	3
<i>stx2</i> , <i>eae</i> , <i>ehxA</i>	0	3	0	1	4
<i>stx2</i>	0	0	1	0	1
Total	42	5	9	4	60


New Zealand. Microbial isolates ( $n=975$ ) obtained from RAMS were analysed by multiplex PCR and of these, 512 isolates were obtained from CT-SMAC (299 isolates were sorbitol fermenters and 213 were sorbitol non-fermenters) and 463 from TBX agar (227 isolates were  $\beta$ -glucuronidase positive and 236 isolates were  $\beta$ -glucuronidase negative). Sixty of the 975 isolates were positive for at least one of the targeted virulence factors of which 47/512 (9.1%) were isolated on CT-SMAC. Of these, a higher proportion of sorbitol fermenters (42/299, 14%) were positive for the targeted virulence factors compared to sorbitol non-fermenters (5/213, 2.3%) ( $\chi^2$  test,  $P=0.00001$ ). Thirteen (2.8%) of the 463 isolated on TBX were positive for the targeted virulence factors. Of these 9/227 (3.9%) of the  $\beta$ -glucuronidase-positive isolates were positive for the targeted virulence factors compared to 4/236 (1.7%) of the  $\beta$ -glucuronidase-negative isolates ( $\chi^2$  test,  $P=0.23$ ). The rate of isolation of *E. coli* isolates with one or more targeted virulence genes was significantly higher on CT-SMAC (47/512, 9.1%) compared to TBX (13/463, 2.8%) ( $\chi^2$  test,  $P<0.0001$ ). The most common combination of the targeted virulence genes in these isolates was *eae*, *ehxA* ( $n=35$ ) followed by *eae* ( $n=9$ ); *ehxA* ( $n=8$ ); *stx2*, *eae*, *ehxA* ( $n=4$ ); *stx1*, *eae*, *ehxA* ( $n=3$ ) and *stx2* ( $n=1$ ) (Table 1). None of the *eae*-positive *stx*-negative strains ( $n=44$ ) were *bfpA*-positive. Two of the three *stx1*, *eae*, *ehxA* isolates were identified

as serogroup O26 using qPCR and the third strain as O71:HR using traditional serological methods. Three of the four *stx2*, *eae*, *ehxA* isolates were identified as O157 using qPCR and the fourth as serogroup O68:H24. The *stx2*-positive isolate was identified as ONT:HNM. Six of the eight *stx*-positive isolates were detected on CT-SMAC and two on TBX ( $\chi^2$  test,  $P=0.35$ ). In total, 53/299 (17.7%) calves were positive for isolates possessing one or more of the targeted virulence genes (*stx1*, *stx2*, *eae*, *ehxA*). Of these 2.6% (8/299) calves were positive for STEC, 12.3% (37/299) for aEPEC and 2.6% (8/299) for *ehxA*. Isolates positive for *eae*, *stx* or *ehxA* or combinations thereof were obtained from the same calf RAMS enrichment broth on seven different occasions (Fig. 1). Isolates having contrasting serogroups were obtained from four of the seven aforementioned RAMS enrichments; serogroup O103 and O145 ( $n=2$ ), serogroup O26 and O145 ( $n=1$ ) and serogroup O145 and an untyped isolate ( $n=1$ ). On all four of these occasions each isolate was *eae*- and *ehxA*-positive only. Untyped isolates EcCa419a and EcCa419b were *eae*- and *ehxA*-positive only but had contrasting PFGE profiles. In contrast to serogroup O145 isolate EcCa388a, that was *eae*- and *ehxA*-positive, an untyped isolate (EcCa388c) from the same animal was *ehxA*-positive only. Untyped strains EcCa412a and EcCa412c were clustered together but appeared to have contrasting PFGE profiles. Finally, serogroup O145 isolates EcCa237a and EcCa237c possessed very similar PFGE profiles and were clustered together indicating that they may have been of a similar genotype.

There was no significant difference in the proportion of calves positive for *E. coli* isolates with one or more targeted virulence genes from Waikato [23.1%, 95% confidence interval (CI) 11.9–40], Manawatu (21.1%, 95% CI 13.1–32) and Taranaki (15.7%, 95% CI 10.3–23) regions (Table 2). Using qPCR, three of the 35 *eae*-, *ehxA*-positive isolates were identified as serogroup O26, seven as O103 and eight as O145. Similarly, using qPCR three of the nine *eae*-positive isolates were identified as serogroup O26. None of the remaining 23 isolates gave a positive result with O26-, O103-, O111-, O145- and O157-specific qPCR primers and their respective serogroups were not determined.

The distribution of the farms from which calves harbouring *E. coli* were obtained in this study is shown in the Figure 2. Isolates positive for the targeted virulence genes were found in all important





**Fig. 1.** Clustering using UPGMA and Dice coefficient of the PFGE profiles of *E. coli* isolates positive for *stx1*, *stx2*, *eae* and *ehxA* from calves with >70% similarity cut-off using *Xba*I. The last lane is the *Salmonella* serotype Braenderup reference standard (H9812). Isolates with the same EcCa numbers were obtained from the same calves.

dairy producing areas of the North Island of New Zealand from which calves were sampled.

Using *Xba*I–PFGE, the 60 isolates from which at least one STEC-associated virulence factor was detected, could be divided into 15 clusters (A–O) with >70% similarity cut-off (Fig. 1). Five of the eight O26 isolates grouped in cluster L; another O26

isolate (*eae*-positive only) was in cluster B and two *eae*-positive O26 isolates could not be genotyped using *Xba*I–PFGE. All seven O103 isolates grouped in cluster I. Of eight O145 isolates, seven were grouped in cluster I and one isolate belonged to cluster O. All O157 isolates ( $n=3$ ) grouped together in cluster M. All O103 isolates present in cluster I were obtained

Table 2. The proportion of recto-anal mucosal swabs positive for *E. coli* isolates containing the targeted virulence genes (*stx1*, *stx2*, *eae*, *ehxA*) collected from 299 bobby calves from three regions of the North Island of New Zealand

Region	No. of samples	Positive for virulence genes	Prevalence, % (95% CI) adjusted for clustering
Taranaki	197	31	15.7 (10.3–23.0)
Manawatu	76	16	21.1 (13.1–32.0)
Waikato	26	6	23.1 (11.9–40.0)
Total	299	53	17.7 (13.2–23.0)

CI, Confidence interval.

from Taranaki ( $n=6$ ) and Manawatu ( $n=1$ ) regions. Of six O103 isolates from Taranaki four were recovered from one farm and the remaining two from two different farms. All O145 isolates in cluster I were obtained from Taranaki from four different farms. Similarly, four of the O26 isolates in cluster L were obtained from four different farms in Taranaki and the one isolate from Manawatu region. All O157 isolates in cluster M were recovered from three different farms in Taranaki region.

## DISCUSSION

Cattle have been identified as a reservoir for both O157 STEC and non-O157 STEC and may provide a source of human infection through direct animal contact and faecally contaminated material, or through environmental contamination. This study has provided evidence that young calves are potentially important carriers of STEC and aEPEC in the North Island of New Zealand. The results of this study should be extrapolated with care as samples were collected from only two abattoirs and the prevalence of STEC and/or aEPEC (*bfpA*-negative EPEC) in other areas of the North Island of New Zealand may be influenced by variables such as the concentration of dairy farms and climatic conditions. As this study aimed to provide a snapshot of the distribution of targeted virulence factors, it is highly likely that the prevalence of both STEC and aEPEC described in this study are underestimates as no preliminary screening method such as an initial screen for *stx* was used. However, the use of two culturing media, selection of four randomly chosen colonies with an absence of screening of enriched samples


for *stx* have provided an opportunity to retrieve *eae*- and/or *ehxA*-positive isolates.

A low proportion of STEC (2.3%) isolates were recovered in this snapshot study with seven *stx*- and *eae*-positive strains and a single *stx*-only isolate obtained. These data are in contrast to a previously described study conducted in the North Island of New Zealand where STEC ( $n=139$ ) were isolated from 53/187 (28.3%) RAMS samples taken from cattle (calves, heifers, dairy cattle) [29]. Furthermore, the prevalence of *stx*-only isolates (48/139, 34.5%) was higher than the prevalence of both *stx*- and *eae*-positive (21/139, 15.1%) isolates and the remaining 70 isolates (50.3%) were *eae*-positive only [29]. Importantly, RAMS were taken from animals of different age groups (calves, heifers, dairy cattle) from four farms in two regions of the lower North Island in the Cookson *et al.* [29] study. A study of STEC in Spanish cattle where faecal samples were collected from calves, heifers and adult cattle over a period of 1 year reported a higher prevalence (8.7%, 36/412). These samples were inoculated onto MacConkey agar and four *E. coli* colonies from each plate were analysed for the presence of *stx*, *eae* and *ehxA* genes [30].

STEC strains of zoonotic importance [1] belonging to serogroups O26, O68, O71 and O157 isolated in this study have previously been isolated from healthy cattle and sheep in New Zealand, Australia and Spain [1, 13, 30]. Further, STEC strains from these serogroups, have been isolated from human cases [1] with STEC O157 and O26 frequently isolated from ruminants and human cases but STEC O68 and O71 only rarely isolated from these hosts [1]. Bettelheim [1] reported isolation of O68 from healthy cattle and human cases on three and seven occasions, respectively. Similarly, O71 have also been isolated from healthy sheep and human cases on two and three occasions, respectively. STEC O71 (*stx1*- and *stx2*-positive) has also been isolated from a diarrhoeic lamb [31].

The zoonotic potential of these serogroups should not be underestimated for two reasons. First, the low isolation of these serogroups may be due to unavailability of standardized isolation methods and second, the recent emergence of STEC O104:H4 in Europe affecting 3222 individuals including 810 HUS cases has shown that less virulent STEC can become highly virulent by acquiring other virulence factors [32].

In our study all STEC O157 isolates were positive for the *stx2* gene whereas all STEC O26 isolates



**Fig. 2.** Map showing distribution of *E. coli* isolates positive for the targeted virulence genes (*stx1*, *stx2*, *eae*, *ehxA*) in the North Island of New Zealand. The data are aggregated to 5×5 km grid cells. If an animal was positive for any of the targeted virulence genes, the grid cell is grey. If the animals sampled were negative the cell is black.

were positive for the *stx1* gene. Previous studies have also reported higher prevalence of *stx2* in STEC O157 isolates [21] and *stx1* in STEC O26 isolates [13]. For example, all STEC O157 isolates ( $n=10$ ) obtained from New Zealand calves were *stx2*-positive [21]. Similarly, Cookson *et al.* [13] reported that all O26 isolates ( $n=2$ ) obtained from cattle were positive for the *stx1* gene.

Previous studies have shown an association between *stx* genotype and STEC virulence. STEC isolates with the *stx2* gene are considered to have high virulence due to their association with HC and HUS cases

[33]. Boerlin *et al.* [33] reported that the rate of isolation of *stx2*-positive isolates was higher (39/60, 60%) from HUS and HC cases than *stx1*-positive isolates (29/75, 38.6%). Another study also found that 12/15 (80%) STEC isolates obtained from HUS and HC cases were positive for *stx2*, one for *stx1* and *stx2* (6.6%) and the remaining two for *stx1* (13.3%) [34].

STEC O26 is also an important human foodborne pathogen and has caused large outbreaks of HUS where the vehicle of infection was food [35]. In contrast to much of the rest of the world, in central and

southern Europe the numbers of human cases of diarrhoeal disease due to STEC O26 are much higher [36]. However, in New Zealand very few human cases due to STEC O26 have been reported and this may be due to underreporting of STEC cases where O26 is not isolated or identified on selective media [37]. Most of the STEC O26 that are associated with human diarrhoeal disease possess *stxI*, *eae* and *ehxA*. In this New Zealand study a typical virulence profile of *stxI*, *eae* and *ehxA* was noted for all the STEC O26 isolates. This virulence profile has public health significance as this is the most common virulence profile observed in STEC O26 isolates from human cases internationally [38].

The proportion of calves positive for aEPEC (12.7%) in this study was estimated to be higher than that of STEC (2.3%). However, there was no difference in prevalence of STEC and aEPEC in cattle in other studies [13, 30]. As for variation with STEC prevalence noted in this study compared to previous work, any variations may be due to differences in sampling and analysis of samples.

Most of the EPEC isolated from ruminants in previous studies lack *bfpA* and are therefore considered as aEPEC [15]. The provenance of aEPEC is uncertain as several studies have shown that aEPEC may eventuate from STEC strains that have lost the *stx*-encoding bacteriophage, or where the complete *E. coli* adherence factor (EAF) plasmid, or the operon encoding *bfpA* on the EAF plasmid has been lost [39, 40]. In contrast, the acquisition of the *stx*-encoding bacteriophage by aEPEC has been reported, suggesting that transition to and from aEPEC and STEC is a dynamic process in complex microbial environments such as ruminant or human gut [41]. To our knowledge there are no instances of isolates being *bfpA*- and *stx*-positive. As isolates positive for *bfpA* and *stx* have not been recognized, the classification of *eae*-positive isolates remains unclear as some may be tEPEC (*bfpA*-positive), others may be aEPEC (EAF plasmid lost) or STEC-like (*stx* genes lost). The prevalence of aEPEC (37/299, 12.3%) in this study was lower than that of a previous study (44% in calves) conducted in the lower North Island of New Zealand [13] but may be due to contrasting study designs. Some of the aEPEC serogroups (O26, O103, O145) isolated in this study may be of zoonotic importance due to their strong association with HC and HUS cases [39].

Although *ehxA* is considered an important virulence marker of STEC due to its association with

disease in humans [42], the role of plasmid-associated enterohaemolysin in human disease is not clearly understood. Most human clinical cases of disease caused by STEC are associated with strains that are *eae*- and *ehxA*-positive [43]; however, some serotypes such as O113:H21 (*eae*-negative, *ehxA*-positive), are notable exceptions [44]. In this study six of the seven isolates were positive for *eae* and *ehxA* indicating their potential for causing disease in humans. However, STEC isolates without *eae* and *ehxA* have been recovered from diarrhoeal and HUS patients on rare occasions [45]. The virulence of *eae*- and *ehxA*-negative isolates should not be underestimated. The recent European outbreak of STEC O104, involving isolates negative for *eae* and *ehxA* further illustrates the potential public health significance of STEC isolates negative for *eae* and *ehxA*. Most of the aEPEC (35/44, 79.5%) in the present study were also positive for *ehxA*. Another study also reported higher detection of plasmid-associated genes such as *ehxA*, *etpD*, *espP* and *katP* in aEPEC (40/80, 50%) compared to tEPEC (6.9%) [46].

CT-SMAC has been frequently used as a selective media for the isolation of STEC O157. However, a previous study has also reported the isolation of STEC serogroups O5, O84, O128 and various non-typable STECs on CT-SMAC [13]. Furthermore, in this study, the STEC O68:H24 strain was isolated on CT-SMAC. Results from this study indicated a higher rate of isolation of *E. coli* isolates with the targeted virulence genes on CT-SMAC compared to TBX ( $\chi^2$  test,  $P < 0.0001$ ) which highlights the benefit of using two different media. Similarly, sorbitol-fermenting *E. coli* isolates were more commonly positive for the targeted virulence genes compared to non-sorbitol-fermenting *E. coli* isolates ( $\chi^2$  test,  $P = 0.00001$ ) indicating the importance of analysing two different colonies on CT-SMAC. A previous study has suggested that some *E. coli* strains, especially those STEC that are *stx*-positive and *eae*-negative, are unable to grow on CT-SMAC [47], therefore an additional medium, TBX, was included to enhance the breadth of *E. coli* that were isolated. The random selection of four colonies (blue, white, grey, purple) provides at least two (potentially four) separate isolates to study in further detail for the distribution of targeted STEC virulence factors. Confining preliminary selection to a single agar medium and/or fermentation characteristic may have limited the breadth of observed allelic profiles recorded. In the study by Cookson *et al.* [13] most *eae*-negative



STEC were isolated from TBX (38/48, 79.16%) compared to CT-SMAC (10/48, 20.84%). However, in this study, where very young calves were sampled, only one *eae*-negative STEC (ONT:HNM) was isolated from TBX. Similarly, in this study aEPEC were isolated more frequently on CT-SMAC ( $n=35$ ) compared to TBX ( $n=10$ ). Cookson *et al.* [29] also reported higher isolation of aEPEC on CT-SMAC (67/70: 41 sorbitol-fermenting, 26 non-sorbitol-fermenting) compared to TBX (3/70). Although it is difficult to compare those studies due to differences in study design, these findings suggest the possibility of underestimation of STEC or EPEC prevalence if a single selective medium is used for isolation of *E. coli*.

PFGE is a molecular epidemiology tool and has been used for subtyping STEC [48]. In this study isolates having the same serogroup generally clustered together with few exceptions. For example, one *E. coli* O145 isolate grouped separately from the remaining seven O145 isolates and one O26 from the remaining O26 isolates. The basis of this differential clustering is unknown. It may be due to the presence of some additional virulence genes which are absent from other isolates. The presence in the same PFGE cluster of similar isolates obtained from different farms in the same region provides evidence of localized geographical clustering of farms positive for various *E. coli* serotypes. For example, O103 isolates obtained from different farms in the same region grouped together by PFGE. A similar trend was observed for O26, O145 and O157 isolates. This geographical clustering may be due to localized transmission of various *E. coli* serogroups between farms in the same region.

This study indicates that STEC and aEPEC of public health significance are present in the bobby calves in New Zealand and therefore, they may represent an important source of environmental contamination and possible human infection. However, studies using molecular characterization and comparison of these isolates with isolates from human cases are required to estimate the nature and potential risk to the human population from these *E. coli*. Additional non-O157 serogroups (O26, O45, O103, O111, O145) have recently been legislated as adulterants by FSIS [5]. Some of these serogroups were isolated in this study where both *stx*-positive and *stx*-negative strains were characterized. Other non-O157 serogroups may have been missed with this snapshot study and more targeted methods such as qPCR or immunomagnetic separation will be required to unequivocally determine their presence.

## ACKNOWLEDGEMENTS

We thank the New Zealand Foundation for Research, Science and Technology for financially supporting this work which contributes to the IMPACT project (contract no. C03X0701). We also thank the Higher Education Commission of Pakistan for providing funds for this study.

## DECLARATION OF INTEREST

None.

## REFERENCES

1. **Bettelheim KA.** The non-O157 Shiga-toxicogenic (Verocytotoxigenic) *Escherichia coli*; under-rated pathogens. *Critical Reviews in Microbiology* 2007; **33**: 67–87.
2. **Swerdlow DL, et al.** A waterborne outbreak in Missouri of *Escherichia coli* O157:H7 associated with bloody diarrhoea and death. *Annals of Internal Medicine* 1992; **117**: 812–819.
3. **Caprioli A, et al.** Enterohaemorrhagic *Escherichia coli*: emerging issues on virulence and modes of transmission. *Veterinary Research* 2005; **36**: 289–311.
4. **Brooks JT, et al.** Non-O157 Shiga toxin-producing *Escherichia coli* infections in the United States, 1983–2002. *Journal of Infectious Diseases* 2005; **192**: 1422–1429.
5. **Food Safety and Inspection Service.** Raw beef product sampling: United States Department of Agriculture, 2013 ([http://www.fsis.usda.gov/wps/wcm/connect/50c9fb74-c0db-48cd-a682-b399ed6b70c0/29\\_IM\\_Raw\\_Beef\\_Prod\\_Sampling.pdf?MOD=AJPERES](http://www.fsis.usda.gov/wps/wcm/connect/50c9fb74-c0db-48cd-a682-b399ed6b70c0/29_IM_Raw_Beef_Prod_Sampling.pdf?MOD=AJPERES)).
6. **Louise CB, Obrig TG.** Specific interaction of *Escherichia coli* O157:H7 derived Shiga like toxin II with human renal endothelial cells. *Journal of Infectious Diseases* 1995; **172**: 1397–1401.
7. **Gyles CL.** Shiga toxin-producing *Escherichia coli*: an overview. *Journal of Animal Science* 2007; **85**: E45–E62.
8. **Paton AW, et al.** Shiga toxin-producing *Escherichia coli* isolates from cases of human disease show enhanced adherence to intestinal epithelial (Henle 407) cells. *Infection and Immunity* 1997; **65**: 3799–3805.
9. **Jerse AE, et al.** A genetic-locus of enteropathogenic *Escherichia coli* necessary for the production of attaching and effacing lesions on tissue-culture cells. *Proceedings of the National Academy of Sciences USA* 1990; **87**: 7839–7843.
10. **Moon HW, et al.** Attaching and effacing activities of rabbit and human enteropathogenic *Escherichia coli* in pig and rabbit intestines. *Infection and Immunity* 1983; **41**: 1340–1351.
11. **Beutin L, et al.** Close association of verotoxin (Shiga-like toxin) production with enterohaemolysin production in strains of *Escherichia coli*. *Journal of Clinical Microbiology* 1989; **27**: 2559–2564.

12. **Taneike I, et al.** Enterohaemolysin operon of Shiga toxin-producing *Escherichia coli*: a virulence function of inflammatory cytokine production from human monocytes. *FEBS Letters* 2002; **524**: 219–224.
13. **Cookson AL, et al.** Serotypes and analysis of distribution of Shiga toxin-producing *Escherichia coli* from cattle and sheep in the lower North Island, New Zealand. *New Zealand Veterinary Journal* 2006; **54**: 78–84.
14. **Kaper JB.** Defining EPEC. *Revista de Microbiologia* 1996; **27**: 130–133.
15. **Trabulsi LR, Keller R, Gomes TAT.** Typical and atypical enteropathogenic *Escherichia coli*. *Emerging Infectious Diseases* 2002; **8**: 508–513.
16. **Wilson MW, Bettelheim KA.** Cytotoxic *Escherichia coli* serotypes. *Lancet* 1980; **1**: 201.
17. **Environmental Science and Research.** Notifiable and other diseases in New Zealand –2011 annual surveillance report, Wellington, 2011 ([http://surv.esr.cri.nz/PDF\\_surveillance/ERL/VTEC/VTEC\\_2011.pdf](http://surv.esr.cri.nz/PDF_surveillance/ERL/VTEC/VTEC_2011.pdf)).
18. **Thorburn D,** Ruminant density, verocytotoxigenic *Escherichia coli* and cryptosporidiosis in New Zealand: descriptive and ecological analyses (thesis). Dunedin: University of Otago, 2010.
19. **French N, et al.** New tools improve our understanding of the epidemiology of food borne pathogens and inform food safety control policies. *Proceedings of the Food Safety, Animal Welfare & Biosecurity Branch of the NZVA*. Hamilton, New Zealand: VetLearn Foundation, 2011.
20. **Cavanagh PD.** Exports. In: Cavanagh PD, ed. *New Zealand Official Yearbook*. Auckland, New Zealand: Statistics New Zealand, Te Tari Tatau, David Bateman Limited, 2003, pp. 533–537.
21. **Irshad H, et al.** Epidemiology of Shiga toxin-producing *Escherichia coli* O157 in very young calves in the North Island of New Zealand. *New Zealand Veterinary Journal* 2012; **60**: 21–26.
22. **Paton AW, Paton JC.** Detection and characterization of Shiga toxigenic *Escherichia coli* by using multiplex PCR assays for *stx1*, *stx2*, *eaeA*, enterohaemorrhagic *E. coli* *hlyA*, *rfbO111*, and *rfbO157*. *Journal of Clinical Microbiology* 1998; **36**: 598–602.
23. **Yokoigawa K, et al.** Primers for amplifying an alanine racemase gene fragment to detect *E. coli* strains in foods. *Journal of Food Science* 1999; **64**: 571–575.
24. **Perelle S, et al.** Detection by 5'-nuclease PCR of Shiga-toxin producing *Escherichia coli* O26, O55, O91, O103, O111, O113, O145 and O157 : H7, associated with the world's most frequent clinical cases. *Molecular and Cellular Probes* 2004; **18**: 185–192.
25. **Fratamico PM, et al.** DNA sequence of the *Escherichia coli* O103 O antigen gene cluster and detection of enterohemorrhagic *E. coli* O103 by PCR amplification of the *wzx* and *wzy* genes. *Canadian Journal of Microbiology* 2005; **51**: 515–522.
26. **Fratamico PM, et al.** PCR detection of enterohemorrhagic *Escherichia coli* O145 in food by targeting genes in the *E. coli* O145 O-antigen gene cluster and the Shiga toxin 1 and Shiga toxin 2 genes. *Foodborne Pathogens and Disease* 2009; **6**: 605–611.
27. **Centers for Disease Control and Prevention.** One-day (24–28 h) standardised laboratory protocol for molecular subtyping of *Escherichia coli* O157:H7, *Salmonella* serotypes, and *Shigella sonnei* by pulsed field gel electrophoresis (<http://www.cdc.gov/pulsenet/PDF/ecoli-shigella-salmonella-pfge-protocol-508c.pdf>), 2009.
28. **Sanson R, Pearson A.** AgriBase – a national spatial farm database. *Epidemiologie et Santé Animale* 1997; **31–32**: 1–3.
29. **Cookson AL, Taylor SCS, Attwood GT.** The prevalence of Shiga toxin-producing *Escherichia coli* in cattle and sheep in the lower North Island, New Zealand. *New Zealand Veterinary Journal* 2006; **54**: 28–33.
30. **Orden JA, et al.** Verotoxin-producing *Escherichia coli* (VTEC), enteropathogenic *E. coli* (EPEC) and necrotoxicogenic *E. coli* (NTEC) isolated from healthy cattle in Spain. *Journal of Applied Microbiology* 2002; **93**: 29–35.
31. **Orden JA, et al.** Typing of the *eae* and *espB* genes of attaching and effacing *Escherichia coli* isolates from ruminants. *Veterinary Microbiology* 2003; **96**: 203–215.
32. **Frank C, et al.** Epidemic profile of Shiga toxin-producing *Escherichia coli* O104:H4 outbreak in Germany – preliminary report. *New England Journal of Medicine* 2011; **365**: 1771–1780.
33. **Boerlin P, et al.** Associations between virulence factors of Shiga toxin-producing *Escherichia coli* and disease in humans. *Journal of Clinical Microbiology* 1999; **37**: 497–503.
34. **Pradel N, et al.** Molecular analysis of Shiga toxin-producing *Escherichia coli* strains isolated from hemolytic-uremic syndrome patients and dairy samples in France. *Applied and Environmental Microbiology* 2008; **74**: 2118–2128.
35. **Hiruta N, Murase T, Okamura N.** An outbreak of diarrhoea due to multiple antimicrobial-resistant Shiga toxin-producing *Escherichia coli* O26:H11 in a nursery. *Epidemiology and Infection* 2001; **127**: 221–227.
36. **Tozzi AE, et al.** Shiga toxin-producing *Escherichia coli* infections associated with hemolytic uremic syndrome, Italy, 1988–2000. *Emerging Infectious Diseases* 2003; **9**: 106–108.
37. **Baker M, et al.** Emergence of Verotoxigenic *Escherichia coli* (VTEC) in New Zealand. Wellington, New Zealand: Environmental Science and Research, 1999 (New Zealand Public Health Report).
38. **Zhang WL, et al.** Molecular characteristics and epidemiological significance of Shiga toxin-producing *Escherichia coli* O26 strains. *Journal of Clinical Microbiology* 2000; **38**: 2134–2140.
39. **Bielaszewska M, et al.** Shiga toxin-negative attaching and effacing *Escherichia coli*: distinct clinical associations with bacterial phylogeny and virulence traits and inferred in-host pathogen evolution. *Clinical Infectious Diseases* 2008; **47**: 208–217.

40. **Hernandes RT, et al.** An overview of atypical enteropathogenic *Escherichia coli*. *FEMS Microbiology Letters* 2009; **297**: 137–149.
41. **Whittam TS, et al.** Clonal relationships among *Escherichia coli* strains that cause haemorrhagic colitis and infantile diarrhoea. *Infection and Immunity* 1993; **61**: 1619–1629.
42. **Schmidt H, Beutin L, Karch H.** Molecular analysis of the plasmid-encoded hemolysin of *Escherichia coli* O157:H7 strain EDL-933. *Infection and Immunity* 1995; **63**: 1055–1061.
43. **Gyles C, et al.** Association of enterohemorrhagic *Escherichia coli* hemolysin with serotypes of Shiga-like-toxin-producing *Escherichia coli* of human and bovine origins. *Applied and Environmental Microbiology* 1998; **64**: 4134–4141.
44. **dos Santos LF, et al.** Set of virulence genes and genetic relatedness of O113:H21 *Escherichia coli* strains isolated from the animal reservoir and human infections in Brazil. *Journal of Medical Microbiology* 2010; **59**: 634–640.
45. **Beutin L, Martin A.** Outbreak of Shiga toxin-producing *Escherichia coli* (STEC) O104:H4 infection in Germany causes a paradigm shift with regard to human pathogenicity of STEC strains. *Journal of Food Protection* 2012; **75**: 408–418.
46. **Bugarel M, et al.** Identification of genetic markers for differentiation of Shiga toxin-producing, enteropathogenic, and avirulent strains of *Escherichia coli* O26. *Applied and Environmental Microbiology* 2011; **77**: 2275–2281.
47. **Fukushima H, Hoshina K, Gomyoda M.** Selective isolation of *eae*-positive strains of shiga toxin-producing *Escherichia coli*. *Journal of Clinical Microbiology* 2000; **38**: 1684–1687.
48. **D'Costa D, et al.** Prevalence, serogroups, Shiga-toxin genes and pulsed field gel electrophoresis analyses of *Escherichia coli* isolated from bovine milk. *Proceedings of the National Academy of Sciences of India, Section B: Biological Sciences* 2013; **83**: 423–429.